Copovidone VA64 is a water-soluble copolymer of vinylpyrrolidone and vinyl acetate used as a pharmaceutical excipient, particularly as a binder and solid-dispersion carrier. Formulators may consider it for wet or dry granulation, tablet production, and solubility-enhancement development, depending on the active pharmaceutical ingredient (API), process, and dosage-form requirements. Its suitability is not automatic: compatibility, process behavior, stability, and applicable quality requirements must be evaluated in the specific formulation.
This guide explains where copovidone VA64 may fit, what to assess before selecting it, and how to approach early formulation screening. It is intended for formulation scientists, pharmaceutical manufacturers, sourcing teams, and product developers comparing excipient options.
Copovidone is a copolymer made from N-vinyl-2-pyrrolidone and vinyl acetate. VA64 commonly denotes a material with a nominal 60:40 composition by weight of vinylpyrrolidone to vinyl acetate. The pyrrolidone component contributes hydrophilic character, while the vinyl acetate component changes the polymer’s overall properties compared with homopolymer povidone.
In a formulation, copovidone is an excipient rather than an active ingredient. It can influence granule formation, tablet integrity, and the physical state of an API in a polymer-based dispersion. These effects depend on the grade, API, excipient combination, manufacturing method, and storage conditions, so formulation-specific testing remains necessary.
“Copovidone” identifies the polymer type, while “VA64” is a commonly used grade designation. Buyers should not assume that products from different suppliers are automatically interchangeable based on the name alone. Confirm the manufacturer’s product identity and compare the current technical and quality documentation before substituting a material.
Start by reviewing the supplier’s specification and certificate of analysis format for the proposed grade. Depending on the supplier and intended use, relevant checks may include appearance, identification, water content, viscosity or solution behavior, residual substances, and microbiological or other quality attributes where applicable. The required limits should be established against your formulation, regulatory strategy, and approved material standards rather than inferred from a grade name.
Also confirm which pharmacopoeial or internal standards the product is represented as meeting, if any, and request supporting documents for evaluation. Do not treat a general product description as proof of a specific certification, regulatory acceptance, or suitability for a particular medicine. Your quality unit should assess documentation and supplier qualification requirements before use.
Copovidone VA64 may be evaluated as a binder in wet granulation or other tablet-manufacturing approaches where binding performance is needed. Its role is to help form granules or support tablet cohesion, but the outcome can vary with solvent, addition method, mixing, drying, compression, and the rest of the formulation. Compare it with established binders in the same process rather than relying on a material description alone.
For initial wet-granulation experiments, formulators sometimes screen binder levels around 2–5% w/w of the formulation. This is an illustrative development range, not a universal recommendation or a supplier specification. The appropriate level depends on the API and process, and should be determined through trials that assess granule properties, tablet performance, and relevant quality attributes.
Copovidone VA64 can also be considered as a polymer carrier when developing solid dispersions for APIs with dissolution or solubility challenges. A polymer may help maintain an API in a dispersed state, but the result depends on API-polymer interactions and the selected manufacturing and storage conditions. Improved dissolution should be demonstrated using a suitable, validated method; it should not be assumed from polymer selection alone.
For more information, please visit NKY Group.
For exploratory studies, teams may compare drug-to-polymer weight ratios such as 1:1, 1:2, and 1:4. These are screening points, not guaranteed optimum ratios or standard formulation targets. The study should also consider process feasibility, residual solvent controls where relevant, physical stability, and whether the resulting dosage form can be manufactured consistently.
In some development programs, copovidone may be assessed in other solid oral dosage-form applications where its binding or polymer-carrier characteristics are relevant. The intended function should be explicit in the formulation brief, because a material that is useful as a binder in one process may not be the preferred choice for another. Confirm suitability through API-specific development work and applicable quality review.
This sequence helps separate a promising excipient hypothesis from demonstrated formulation performance. It also makes it easier to compare copovidone VA64 with alternatives such as povidone, hydroxypropyl cellulose, or other polymers on a defined basis. The best comparison is one that uses the same API, process conditions, and performance criteria.
Copovidone VA64 pricing and availability can vary with grade, origin, order quantity, packaging, shipping destination, and current supply conditions. Minimum order quantity (MOQ) and lead time are supplier- and order-specific, so they should be confirmed for the required product and delivery location. Avoid basing a sourcing decision on an indicative price without checking what specification and commercial terms it covers.
For development purchases, ask whether sample or smaller evaluation quantities are available and whether they come with documentation suitable for your review. For commercial planning, confirm packaging configuration, shelf-life information, storage guidance, order lead time, and the process for communicating specification or supply changes. These details help your technical and procurement teams assess the full sourcing fit.
These questions help distinguish a technically suitable material from a sourcing arrangement that may be difficult to qualify or maintain. Supplier responses should be checked against your internal procedures; a helpful sales discussion does not replace formal quality assessment. Where more than one source is being considered, compare documentation and supply terms alongside price.
At NKY Group, we support B2B buyers evaluating copovidone VA64 by discussing product requirements, intended application, and sourcing needs. Share your target grade or specification, intended use, required quantity, destination, and documentation expectations so we can assess the appropriate product and commercial details. Product availability, MOQ, lead time, and documentation should be confirmed for each inquiry.
For development teams, a clear request can include whether the material is being considered for granulation or a solid-dispersion study, along with any critical quality or packaging requirements. This helps align supplier information with your technical review. Final excipient selection and approval remain the responsibility of the buyer’s formulation, quality, and regulatory teams.
Copovidone VA64 may be a useful candidate when a formulation requires a polymeric binder or a carrier for solid-dispersion development. Its nominal 60:40 vinylpyrrolidone-to-vinyl acetate composition provides a starting point for understanding the material, but it does not predict performance in a specific medicine. Confirm the grade and documentation, then evaluate the polymer through API- and process-specific studies.
Your next step is to define the formulation goal, agree on measurable screening criteria, and request the relevant specification and sourcing details from potential suppliers. If you are assessing copovidone VA64 for an upcoming project, contact NKY Group with your application, target requirements, quantity, and destination to discuss a suitable sourcing inquiry.
Contact us to discuss your requirements of copovidone va64. Our experienced sales team can help you identify the options that best suit your needs.
Comments
Please Join Us to post.
0